Skye Bioscience director gets 35,000 stock options

Q: What insider transaction did Skye Bioscience (SKYE) report in this Form 4?

Skye Bioscience reported a stock option grant to director Annalisa Jenkins covering 35,000 shares on February 6, 2026. The filing shows this as an acquisition of derivative securities, not an open-market stock purchase or sale.

Q: Who is the insider involved in the latest Skye Bioscience (SKYE) Form 4?

The insider is Annalisa Jenkins, a director of Skye Bioscience. The Form 4 indicates she filed individually and reports her receipt of 35,000 stock options linked to the company’s common stock as part of her compensation.

Q: How many Skye Bioscience shares are covered by the new stock options?

The new stock option grant covers 35,000 shares of common stock. This figure represents the total number of underlying shares tied to the derivative security reported, and it equals the number of options Jenkins beneficially owns following the transaction.

Q: What is the exercise price and expiration date of the Skye Bioscience options?

The stock options have an exercise price of $0.82 per share and an expiration date of February 6, 2036. These terms define the price Jenkins must pay to buy shares and the last date she can exercise the options.

Q: How do the Skye Bioscience (SKYE) director’s options vest over time?

The options vest in equal monthly installments over a one-year period beginning January 19, 2026. This means portions of the 35,000-share grant become exercisable each month until the full award is vested after one year.

Q: Is the Skye Bioscience Form 4 transaction a direct or indirect holding?

The Form 4 identifies the 35,000 stock options as held directly by Annalisa Jenkins. There is no indication of indirect ownership through entities such as trusts or partnerships in the ownership description provided.

Skye Bioscience director Annalisa Jenkins received a grant of stock options covering 35,000 shares of common stock on February 6, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Skye Bioscience director Annalisa Jenkins received a grant of stock options covering 35,000 shares of common stock on February 6, 2026. The options have an exercise price of $0.82 per share and expire on February 6, 2036.

According to the filing, the option vests in equal monthly installments over a one-year period beginning January 19, 2026. After this grant, Jenkins beneficially owns 35,000 stock options, held directly.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 1 txn

Insider Jenkins Annalisa

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	35,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 35,000 contracts (Direct)

Footnotes (1)

F1. The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Skye Bioscience (SKYE) report in this Form 4?

Skye Bioscience reported a stock option grant to director Annalisa Jenkins covering 35,000 shares on February 6, 2026. The filing shows this as an acquisition of derivative securities, not an open-market stock purchase or sale.

Who is the insider involved in the latest Skye Bioscience (SKYE) Form 4?

The insider is Annalisa Jenkins, a director of Skye Bioscience. The Form 4 indicates she filed individually and reports her receipt of 35,000 stock options linked to the company’s common stock as part of her compensation.

How many Skye Bioscience shares are covered by the new stock options?

The new stock option grant covers 35,000 shares of common stock. This figure represents the total number of underlying shares tied to the derivative security reported, and it equals the number of options Jenkins beneficially owns following the transaction.

What is the exercise price and expiration date of the Skye Bioscience options?

The stock options have an exercise price of $0.82 per share and an expiration date of February 6, 2036. These terms define the price Jenkins must pay to buy shares and the last date she can exercise the options.

How do the Skye Bioscience (SKYE) director’s options vest over time?

The options vest in equal monthly installments over a one-year period beginning January 19, 2026. This means portions of the 35,000-share grant become exercisable each month until the full award is vested after one year.

Is the Skye Bioscience Form 4 transaction a direct or indirect holding?

The Form 4 identifies the 35,000 stock options as held directly by Annalisa Jenkins. There is no indication of indirect ownership through entities such as trusts or partnerships in the ownership description provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/09/2026 - 08:54 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jenkins Annalisa

(Last)

(First)

(Middle)

11250 EL CAMINO REAL

SUITE 100

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.82	02/06/2026		A		35,000		⁽¹⁾	02/06/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026.

Remarks:

	/s/ Kaitlyn Arsenault, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR